ErinGourleyReidMDMS

Hematology • La Jolla, CA

Professor, Medicine, UCSD School of Medicine

Join to view full profile

Dr. Reid is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Reid's full profile

Already have an account?

Office
3855 HEALTH SCIENCES DR Rm 2238
Moores UCSD Cancer Center
La Jolla, CA 92093
Phone+1 858-822-6276

Fax+1 858-822-6288

Summary

Dr. Erin Reid is a hematologist in La Jolla, CA and is affiliated with UC San Diego Health. She received her medical degree from UCSF, training at Stanford, & has been in practice for over 20 years. She is experienced lymphomas with a research focus in HIV/AIDS-related lymphoma and Kaposi sarcoma, and serves in national leadership roles within the AIDS Malignancy Consortium (AMC), NCCN, and ASH.

Education & Training

Stanford UniversityM.S., Epidemiology/Clinical Research, 2003 - 2006
University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2004
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2001 - 2004
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2000 - 2001
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1999 - 2000
University of California San Francisco School of MedicineClass of 1999
Stanford UniversityBS, Biology, Phi Beta Kappa, Honors, 1990 - 1994

Certifications & Licensure

CA State Medical License 2000 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Top Doctors:San Diego Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Valproic Acid in Treating Patients With Kaposi's Sarcoma Start of enrollment: 2005 Feb 01
Completed
Not Applicable
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma Start of enrollment: 2005 Jun 01
Completed
Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Start of enrollment: 2006 Sep 01
Completed
Phase 2
Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma Start of enrollment: 2007 Oct 01
Completed
Phase 1
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma Start of enrollment: 2007 Nov 01
Completed
Phase 1
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma Start of enrollment: 2008 Sep 01
Terminated
Phase 1, Phase 2
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Start of enrollment: 2009 Jul 24
Completed
Phase 3
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients Start of enrollment: 2009 Oct 01
Completed
Phase 2
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma Start of enrollment: 2009 Aug 01
Completed
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma Start of enrollment: 2010 Jan 22
Completed
Phase 1
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Start of enrollment: 2010 Aug 27
Completed
Phase 1, Phase 2
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma Start of enrollment: 2010 Mar 25
Completed
Phase 2
Autologous Transplant in HIV Patients (BMT CTN 0803) Start of enrollment: 2010 Apr 01
Completed
Phase 2
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Start of enrollment: 2010 Oct 06
Completed
Phase 1, Phase 2
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy Start of enrollment: 2011 Apr 04
Terminated
Phase 3
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Apr 08
Active, not recruiting
Phase 2
Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy Start of enrollment: 2011 Jun 01
Terminated
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Start of enrollment: 2014 May 01
Unknown status
Phase 1
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma Start of enrollment: 2015 Jun 01
Completed
Phase 2
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) Start of enrollment: 2016 Mar 01
Completed
Phase 1
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Start of enrollment: 2016 Jun 23
Active, not recruiting
Phase 1, Phase 2
sEphB4-HSA in Treating Patients With Kaposi Sarcoma Start of enrollment: 2018 Feb 13
Recruiting
Phase 2
Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma Start of enrollment: 2016 Oct 11
Terminated
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2018 Aug 01
Completed
Phase 2
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas Start of enrollment: 2019 Apr 30
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

46 citations
Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.
Susan E. Krown, Debasmita Roy, Jeannette Y. Lee, Bruce J. Dezube, Erin Reid
Journal of Acquired Immune Deficiency Syndromes. 2012-04-15
19 citations
Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies.
Erin Reid
Current Opinion in Oncology. 2011-09-01
19 citations
The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy
Paolo Caimi, Kirit M. Ardeshna, Erin Reid, Weiyun Z. Ai, Matthew A. Lunning
Clinical Lymphoma, Myeloma & Leukemia. 2021-11-12

Journal Articles

Venetoclax, Bendamustine, and Rituximab in Patients with Relapsed or Refractory NHL: A Phase 1b Dose-Finding Study
N Fowler, E Reid, L J Nastoupil, Annals of Oncology

Abstracts/Posters

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-HodgkinÍs Lymphoma and C...
Erin G. Reid, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
Erin G. Reid, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
Erin G. Reid, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatm...
Erin G. Reid, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085
Erin G. Reid, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Press Mentions

How Much Work Are You Really Supposed to Do at Work?September 27th, 2021
Expert Q&A: Understanding the Oncogenic Role of HIV in Burkitt LymphomaAugust 27th, 2020
Three Things Lockdowns Have Exposed About Working and ParentingApril 27th, 2020
Join now to see all